A Phase 1 Bioavailability and Food Effect Study to Compare Tablet Versus Solution Formulation and to Assess the Effect of Food on the Bioavailability of a Single TAK-935 Dose in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2016
At a glance
- Drugs TAK 935 (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Takeda
- 15 Nov 2016 Status changed from recruiting to completed.
- 06 Oct 2016 Status changed from not yet recruiting to recruiting.
- 29 Sep 2016 New trial record